These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 14676992

  • 1. The effect of 1-year transdermal estrogen replacement therapy on bone mineral density and biochemical markers of bone turnover in osteopenic postmenopausal systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
    Bhattoa HP, Bettembuk P, Balogh A, Szegedi G, Kiss E.
    Osteoporos Int; 2004 May; 15(5):396-404. PubMed ID: 14676992
    [Abstract] [Full Text] [Related]

  • 2. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
    Arrenbrecht S, Boermans AJ.
    Osteoporos Int; 2002 May; 13(2):176-83. PubMed ID: 11908492
    [Abstract] [Full Text] [Related]

  • 3. Pulsed estrogen therapy in prevention of postmenopausal osteoporosis. A 2-year randomized, double blind, placebo-controlled study.
    Nielsen TF, Ravn P, Bagger YZ, Warming L, Christiansen C.
    Osteoporos Int; 2004 Feb; 15(2):168-74. PubMed ID: 14647880
    [Abstract] [Full Text] [Related]

  • 4. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.
    Delmas PD, Pornel B, Felsenberg D, Garnero P, Hardy P, Pilate C, Dain MP.
    Bone; 1999 May; 24(5):517-23. PubMed ID: 10321913
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
    Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, D'Anna R, Corrado F, Pizzoleo MA, Cincotta M, Altavilla D, Ientile R, Squadrito F.
    J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
    [Abstract] [Full Text] [Related]

  • 7. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial.
    Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M.
    JAMA; 2003 Aug 27; 290(8):1042-8. PubMed ID: 12941676
    [Abstract] [Full Text] [Related]

  • 8. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
    Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.
    Osteoporos Int; 2005 Apr 27; 16(4):372-9. PubMed ID: 15654581
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
    Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB.
    Osteoporos Int; 2003 Oct 27; 14(10):814-22. PubMed ID: 14610642
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
    Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.
    JAMA; 2003 Oct 27; 287(20):2668-76. PubMed ID: 12020302
    [Abstract] [Full Text] [Related]

  • 14. Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women.
    Huang AJ, Ettinger B, Vittinghoff E, Ensrud KE, Johnson KC, Cummings SR.
    J Bone Miner Res; 2007 Nov 27; 22(11):1791-7. PubMed ID: 17620054
    [Abstract] [Full Text] [Related]

  • 15. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH, Ensrud KE, Burdeska A, Mills T, Oral Ibandronate Study Group.
    J Bone Miner Res; 2004 Jan 27; 19(1):11-8. PubMed ID: 14753731
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia].
    Insua A, Negri A, Zanchetta JR.
    Medicina (B Aires); 1995 Jan 27; 55(5 Pt 1):408-14. PubMed ID: 8728770
    [Abstract] [Full Text] [Related]

  • 18. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
    Schaefers M, Muysers C, Alexandersen P, Christiansen C.
    Menopause; 2009 Jan 27; 16(3):559-65. PubMed ID: 19423999
    [Abstract] [Full Text] [Related]

  • 19. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A, Glover SJ, Eastell R.
    Bone; 2009 Dec 27; 45(6):1044-52. PubMed ID: 19665601
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.